New Research Reveals How to Make Ketamine’s Antidepressant Effects Last Longer
Ketamine works fast against depression. That much scientists have known for years. But the relief fades quickly, often within days. A new study published in Molecular Psychiatry may have found the key to changing that. Researchers discovered that suppressing a single enzyme called NOX-1 can extend ketamine’s antidepressant effects and restore activity in brain circuits linked to depression.
New:Â Get Pre-Screened for a Psychedelic Clinical Trial
| Key Takeaway | Detail |
|---|---|
| The Problem | Ketamine’s antidepressant effects wear off quickly after a single dose |
| The Discovery | Suppressing the enzyme NOX-1 extends ketamine’s therapeutic window |
| The Compound | A novel AMPA receptor modulator called K-4 naturally lowers NOX-1 |
| Duration Improvement | K-4’s effects persisted for 7 days after treatment ended |
| Brain Circuits Affected | Medial prefrontal cortex and lateral habenula showed restored activity |
| Clinical Implication | Combining a NOX-1 inhibitor with ketamine could reduce treatment frequency |
A Molecular Missing Piece
The research team tested a new compound called K-4. It works differently from ketamine. Instead of blocking NMDA receptors, K-4 boosts AMPA receptors. Both receptor types play critical roles in mood regulation.
In animal models of treatment resistant depression, K-4 produced antidepressant effects that outlasted ketamine’s. The behavioral improvements held for seven days after the drug was stopped. Ketamine’s benefits, by comparison, dissipated much sooner.
Why NOX-1 Matters
The breakthrough came from RNA sequencing. Researchers analyzed gene expression in the medial prefrontal cortex, a brain region central to depression. They found that K-4 dramatically reduced levels of NADPH oxidase 1, or NOX-1. Ketamine lowered NOX-1 too, but not as much.
NOX-1 generates oxidative stress, which damages neurons and disrupts signaling. Less NOX-1 means less oxidative damage in the brain areas that regulate mood. Recent imaging research has also shown how ketamine physically rewires neural circuits in depressed brains, and this new finding adds another layer to that picture.
Extending Ketamine’s Reach
The team then ran a critical test. They gave ketamine alongside a NOX-1 inhibitor. The combination prolonged ketamine’s antidepressant effects and quieted abnormal firing in the lateral habenula. This brain region acts as the brain’s “disappointment center.” Overactivity there drives depressive symptoms.
When researchers blocked AMPA receptors, the extended benefits disappeared. This confirmed that the sustained effects depend on AMPA receptor signaling working together with NOX-1 suppression.
What This Means for Treatment
For the millions who rely on ketamine infusions or nasal spray treatments, the implications are significant. Current protocols often require repeated sessions to maintain benefits. A combination approach targeting NOX-1 could stretch each treatment further and reduce the burden on patients.
This research remains in preclinical stages. Human trials will determine whether the same mechanisms hold. But the findings open a clear path toward longer lasting ketamine therapy, one that could reshape how clinicians approach treatment resistant depression.
Related provider: Axis Stem Cell Institute
Related provider: Dynamic Ketamine and Infusions
Related providers:
Related providers:
See also: — our ketamine therapy resources.
Related providers:
Related providers:
Related providers:
Related providers:
Related providers:
Related providers:
Related provider: Revitalize Health ‘ Med Spa
Related providers:
